CURCUMINOID COMPOSITION FOR THERAPEUTIC MANAGEMENT OF METABOLIC SYNDROME
申请人:Majeed Muhammed
公开号:US20210106543A1
公开(公告)日:2021-04-15
The present invention discloses a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids and its therapeutic application. More specifically, the present invention discloses the use of a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids in the therapeutic management of metabolic syndrome in mammals.
CURCUMINOID COMPOSITION AND ITS THERAPEUTIC POTENTIAL IN MANAGING LUNG FIBROSIS
申请人:Majeed Muhammed
公开号:US20210106544A1
公开(公告)日:2021-04-15
The present invention discloses a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids and its therapeutic application. More specifically, the present invention discloses the use of a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids in the therapeutic management of interstitial lung disease or lung fibrosis.
[EN] CURCUMINOID COMPOSITION AND ITS THERAPEUTIC POTENTIAL IN MANAGING LUNG FIBROSIS<br/>[FR] COMPOSITION DE CURCUMINOÏDE ET SON POTENTIEL THÉRAPEUTIQUE DANS LA PRISE EN CHARGE DE LA FIBROSE PULMONAIRE
申请人:MAJEED MUHAMMED
公开号:WO2021076771A1
公开(公告)日:2021-04-22
The present invention discloses a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids and its therapeutic application. More specifically, the present invention discloses the use of a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w7w hexahydrocurcuminoids and 5%- 10% w7w octahydrocurcuminoids in the therapeutic management of interstitial lung disease or lung fibrosis.
[EN] CURCUMINOID COMPOSITION FOR THERAPEUTIC MANAGEMENT OF METABOLIC SYNDROME<br/>[FR] COMPOSITION DE CURCUMINOÏDES DESTINÉE À LA PRISE EN CHARGE THÉRAPEUTIQUE DU SYNDROME MÉTABOLIQUE
申请人:MAJEED MUHAMMED
公开号:WO2021076766A1
公开(公告)日:2021-04-22
The present invention discloses a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids and its therapeutic application. More specifically, the present invention discloses the use of a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%- 10% w/w octahydrocurcuminoids in the therapeutic management of metabolic syndrome in mammals.
Biarylheptanoids and other constituents from wood of Alnus japonica
Abstract The wood of Alnus japonica has been shown to contain a number of biarylheptanoids as well as other phenolics, including secoisolariciresinol diferulate. The co-occurrence of cyclized biarylheptanoids with their corresponding acyclic biarylheptanoids has been demonstrated and this fact may have biosynthetic significance. The possible chemotaxonomic importance of biarylheptanoids in members